학술논문
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial
Document Type
Article
Author
Guigay, J.; Ortholan, C.; Vansteene, D.; Cupissol, D.; Even, C.; Kaminsky, M.-C.; Sire, C.; Blot, E.; Debourdeau, P.; Bozec, L.; Saada-Bouzid, E.; Michel, C.; Fayette, J.; Dalloz, P.; Pointreau, Y.; Caer, H.L.; Falandry, C.; Digue, L.; Braccini, A.; Lopez, S.; Guillet, P.; Cheurfa, N.; Schwob, D.; Aupérin, A.; Bourhis, J.; Mertens, C.
Source
In: The Lancet Healthy Longevity . (The Lancet Healthy Longevity, March 2024, 5(3):e182-e193)
Subject
Language
English
ISSN
26667568